U.S. Markets open in 8 hrs 24 mins

Aelan Cell Technologies Names Kathryn N. Ivey, Ph.D. to Its Scientific Advisory Board

Kathryn N. Ivey, Ph.D. joins Aelan Cell Technologies' scientific advisory board Click here for high-resolution version

SAN FRANCISCO, CA--(Marketwired - Jan 6, 2016) -  Aelan Cell Technologies announced today the appointment of Kathryn N. Ivey, Ph.D., to its Scientific Advisory Board. Dr. Ivey is the Director of the Gladstone Stem Cell Core at the Gladstone Institutes and manages BioFulcrum, an enterprise within the Gladstone Institutes aimed at accelerating the timeline for finding cures to currently untreatable diseases by partnering with scientists, non-profits and industries.

Dr. Ivey has spent the last 15 years studying cardiac cell fate and behavior. She has conducted research using both animal and cellular models to interrogate molecular networks that control processes during heart development and whose disruption can cause cardiac disease. Currently, her research involves using induced pluripotent stem cells (iPSCs) to model cardiac and skeletal muscle development and disease to attempt to reveal cellular and molecular processes that go wrong, leading to various pathological diseases. 

Victoria Lunyak, Ph.D., the President and CEO of Aelan, said: "Dr. Ivey's work with iPSCs falls directly in line with much of the work we are already doing at Aelan. We are pleased to add her expertise to our team of cutting edge clinicians and researchers."

"As Aelan continues to grow, we're excited to have Dr. Ivey as the next accomplished scientist joining our team," added Chester Aldridge, Chairman of Aelan's Board of Directors and CEO of U.S. Equity Holdings. "Dr. Ivey's knowledge of and background in stem cell research will be a great asset to Aelan moving forward."

As the Director of the Gladstone Stem Cell Core, Dr. Ivey oversees the administration of a Shared Research Facility, manages and directs a team of Research Associates who provide technical support to human iPSC-based research projects for Gladstone investigators, and contributes to projects involving disease modeling using iPSC technology.

In her role as the Scientific Program Manager of BioFulcrum, Dr. Ivey works closely with the Partners and Executive Team to plan and coordinate scientific endeavors. Her responsibilities include overseeing scientific projects from start to finish, ensuring goals and milestones are achieved, providing scientific content for communication to key stakeholders, assisting in managing the budget, reporting progress both internally and externally, overseeing research compliance, and facilitating protocol applications as needed.

"I have focused my studies and my career on cell biology and stem cell biology, as well as regenerative medicine," Dr. Ivey said. "Aelan is already doing exciting work in these fields, and I'm looking forward to advising Aelan as the company continues to take on groundbreaking research and development efforts."

Dr. Ivey earned her Bachelor's Degree at Texas A&M University and her Ph.D. in molecular and cell biology at the University of Texas Southwestern Medical Center in Dallas. At UT, she studied transcriptional regulation of the developing heart. After earning her Ph.D., Dr. Ivey joined Gladstone as a postdoctoral scholar and studied stem cell biology as a California Institute for Regenerative Medicine Scholar.

About Aelan Cell Technologies:
Aelan Cell Technologies is a San Francisco startup engaged in the research, discovery, development and commercialization of innovative biomedical technologies for the advancement of human health and longevity. With a growing intellectual property portfolio of disruptive technologies and medical tools, Aelan has assembled an experienced team -- bringing together scientific and business expertise -- to successfully lead its products through each phase of development.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2945489